Objective
Monoclonal antibodies have received much attention because of their potential application to therapy in man. However, in order to reduce the immunogenicity of these reagents, it is very desirable that the administered monoclonal antibodies are of human origin.
Major problems have been encountered in preparing monoclonal antibodies of human origin. In particular, it will be difficult to circumvent the ethical and humane hurdles implicit in immunizing human volunteers.
Two major alternative approaches to the isolation of human monoclonal antibodies have been put forward:the phage display and transgenic mouse approaches, each of which has their particular advantages. At present, neither approach is fully developed but we anticipate that the two approaches might ultimately prove complementary.
It is the object of this application to finalize the development and application of the transgenic mouse approach. The advantage of this approach is that once the creation of the suitable mouse strain is finalized, it should be possible to isolate high affinity human antibodies to human antigens using entirely conventional and user-friendly technology.
The engineered mouse strain will contain human immunoglobulin heavy and light chain gene loci in germline configuration. These loci can undergo gene rearrangement yielding a population of mouse lymphocytes expressing a diverse array of human immunoglobulin molecules; antigen challenge of these mice in the conventional way can then lead to the establishment of antigen-specific hybridomas that secrete human monoclonal antibodies. The mouse immunoglobulin loci in these animals will carry targeted disruptions to facilitate human antibody isolation.
The creation of a suitable mouse strain is in its near final stages and the data obtained so far are extremely encouraging. The object of the work described in this application is - as part of an intra-European collaboration to finalize the creation of and evaluate the first line of mice from which high affinity human antibodies can be isolated, to obtain and test human monoclonals of potential therapeutic benefit and to initiate further experiments on antibody selection and diversification so as to facilitate the development of further, improved strains of transgenic mice.
Fields of science (EuroSciVoc)
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
You need to log in or register to use this function
Programme(s)
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Topic(s)
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Call for proposal
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
Data not available
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
Funding Scheme
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
Coordinator
CB2 2QH Cambridge
United Kingdom
The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.